{
  "docId": "019de077-19d1-772e-933a-c7f1c42d9b04",
  "docSlug": "d223628377f56d072b5dbf426c21baf1",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 37,
  "pageCount": 42,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 7,
  "notes": "The slide uses a comparative framework to contrast the 2L+ (salvage) and 1L (front-line) market opportunities.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-19d1-772e-933a-c7f1c42d9b04/37",
  "deckHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04",
  "deckJsonHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04.json",
  "deckAnchorHref": "/decks/019de077-19d1-772e-933a-c7f1c42d9b04#slide-37",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.56,
        "y": 0.43
      },
      "kind": "list",
      "text": "Potential to address combined medical needs: ROS1 mutation coverage + CNS activity + avoiding off-target adverse events; Opportunity to drive deep, durable responses; Favorable preliminary safety profile consistent with ROS1-selective, TRK-sparing design",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4129be03-c118-4062-971b-9659753f12cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.35,
        "x": 0.13,
        "y": 0.43
      },
      "kind": "list",
      "text": "Clinical activity observed in heavily pretreated patients with ROS1+ NSCLC: Who likely exhausted all available therapies, including after lorlatinib or repotrectinib (ORR: 50%); With ROS1 resistance mutations (ORR: 78%); With history of CNS metastasis (ORR: 73%) including intracranial responses (3/3 PRs); FDA Breakthrough Therapy Designation granted for the treatment of patients with ROS1+ metastatic NSCLC who have been previously treated with two or more ROS1 TKIs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1b0ba09-1dfd-4431-aeb0-17c1adc1f489",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.058,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "Sources: Cortellis Sales and Forecasts, accessed November 2023; Lin et al., J Thorac Oncol 2017; Gainor et al, JCO Precision Oncol 2017; Ou and Zhu Lung Cancer 2019; Patil et al, JTO 2018; Drilon A., EORTC-NCI-AACR 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "614a2f27-3863-449f-9582-4c8a11fb8486",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.65,
        "x": 0.058,
        "y": 0.185
      },
      "kind": "title",
      "text": "Opportunity to both move up the treatment paradigm & grow the market with deep, durable responses",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c483ac6-36a0-4be7-b7da-8a98d99bb631",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.058,
        "y": 0.115
      },
      "kind": "title",
      "text": "Potential Best-in-class Profile for ROS1+ NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce0d65be-53a5-4bed-bd33-859c6ffb311c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "1199c300-c941-4266-9444-14b87097ea1b",
      "evidence": "Side-by-side comparison of 2L+ and 1L treatment paradigms",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}